"Proton pump inhibitors (PPIs) are associated with increased risk for chronic kidney disease (CKD), according to two population-based analyses published online January 11 in JAMA Internal Medicine. The authors suggest the widely used drugs "...
Cytomegalovirus Immune Globulin Intravenous (Human) is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart. In transplants of these organs other than kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir.
DOSAGE AND ADMINISTRATION
The maximum recommended total dosage per infusion is 150 mg Ig/kg, administered according to the following schedule:
Type of Transplant
|Kidney||Liver, Pancreas, Lung, Heart|
|Within 72 hours of transplant:||150 mg/kg||150 mg/kg|
|2 weeks post transplant:||100 mg/kg||150 mg/kg|
|4 weeks post transplant:||100 mg/kg||150 mg/kg|
|6 weeks post transplant:||100 mg/kg||150 mg/kg|
|8 weeks post transplant:||100 mg/kg||150 mg/kg|
|12 weeks post transplant:||50 mg/kg||100 mg/kg|
|16 weeks post transplant:||50 mg/kg||100 mg/kg|
Preparation for Administration
Remove the tab portion of the vial cap and clean the rubber stopper with 70% alcohol or equivalent. DO NOT SHAKE VIAL; AVOID FOAMING.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Infuse the solution only if it is colorless, free of particulate matter and not turbid.
Infusion should begin within 6 hours after entering the vial and should be complete within 12 hours of entering the vial. Vital signs should be taken preinfusion, mid-way and post-infusion as well as before any rate increase. Cytogam® (cytomegalovirus immune globulin intravenous human) should be administered through an intravenous line using an administration set that contains an in-line filter (pore size 15µ) and a constant infusion pump (i.e., IVAC pump or equivalent). A smaller in-line filter (0.2µ) is also acceptable. Pre-dilution of Cytogam® (cytomegalovirus immune globulin intravenous human) before infusion is not recommended. Cytogam® (cytomegalovirus immune globulin intravenous human) should be administered through a separate intravenous line. If this is not possible, Cytogam® (cytomegalovirus immune globulin intravenous human) may be "piggybacked" into a pre-existing line if that line contains either Sodium Chloride Injection, USP, or one of the following dextrose solutions (with or without NaCl added): 2.5% dextrose in water, 5% dextrose in water, 10% dextrose in water, 20% dextrose in water. If a pre-existing line must be used, the Cytogam® (cytomegalovirus immune globulin intravenous human) should not be diluted more than 1:2 with any of the above-named solutions. Admixtures of Cytogam® (cytomegalovirus immune globulin intravenous human) with any other solutions have not been evaluated.
Administer intravenously at 15 mg Ig per kg body weight per hour. If no adverse reactions occur after 30 minutes, the rate may be increased to 30 mg Ig/kg/hr; if no adverse reactions occur after a subsequent 30 minutes, then the infusion may be increased to 60 mg Ig/kg/hr (volume not to exceed 75 mL/hour). DO NOT EXCEED THIS RATE OF ADMINISTRATION. The patient should be monitored closely during and after each rate change.
Administer at 15 mg Ig/kg/hr for 15 minutes. If no adverse reactions occur, increase to 30 mg Ig/kg/hr for 15 minutes and then increase to a maximum rate of 60 mg Ig/kg/hr (volume not to exceed 75 mL/hour). DO NOT EXCEED THIS RATE OF ADMINISTRATION. The patient should be monitored closely during each rate change.
Cytogam® (cytomegalovirus immune globulin intravenous human) should be used with caution in patients with pre-existing renal insufficiency and in patients judged to be at increased risk of developing renal insufficiency (including, but not limited to those with diabetes mellitus, age greater than 65, volume depletion, paraproteinemia, sepsis and patients receiving known nephrotoxic drugs). In these cases especially, it is important to assure that patients are not volume depleted prior to Cytogam® (cytomegalovirus immune globulin intravenous human) infusion. While most cases of renal insufficiency have occurred in patients receiving total doses of 350 mg Ig/kg or greater, no prospective data are presently available to identify a maximum safe dose, concentration or rate of infusion in patients determined to be at increased risk of acute renal failure. In the absence of prospective data, recommended doses should not be exceeded and the concentration and infusion rate selected should be the minimum practicable.
Potential adverse reactions are: flushing, chills, muscle cramps, back pain, fever, nausea, vomiting, wheezing, drop in blood pressure. Minor adverse reactions have been infusion rate related - if the patient develops a minor side effect (i.e., nausea, back pain, flushing), slow the rate or temporarily interrupt the infusion. If anaphylaxis or drop in blood pressure occurs, discontinue infusion and use antidote such as diphenhydramine and adrenalin.
To prevent the transmission of hepatitis viruses or other infectious agents from one person to another, sterile disposable syringes and needles should be used. The syringes and needles should not be reused.
Cytogam®, Cytomegalovirus Immune Globulin Intravenous (Human), is supplied in one single-dose vial form:
|NDC No.||Total Quantity of Immunoglobulin||Volume||Concentration|
|44206-3101-1||2500 mg ± 500 mg||50mL||50 ± 10 mg/mL|
Cytogam® (cytomegalovirus immune globulin intravenous human) should be stored between 2-8°C (36-46°F), and used within 6 hours after entering the vial.
For additional information concerning Cytomegalovirus Immune Globulin Intravenous (Human) contact: CSL Behring Medical Affairs, CSL Behring LLC, King of Prussia, PA 19406 USA. 1-800-504-5434
Manufactured by: PRECISION PHARMA SERVICES, Melville, NY 11747, USA. and by: BAXTER PHARMACEUTICAL SOLUTIONS, LLC, Bloomington, IN 47403. Manufactured for: CSL Behring AG, Bern, Switzerland. Revised March 2007. FDA rev date: n/aThis monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/30/2008
Additional Cytogam Information
Cytogam - User Reviews
Cytogam User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.